NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP alerts investors in ImmunityBio, Inc. (NASDAQ: IBRX) of a pending securities class action naming a senior executive as an individual defendant. Class Period: January 19, 2026 through March 24, 2026. Find out if you qualify to recover losses or contact Joseph E. Levi, Esq. at [email protected] | (212) 363-7500.
IBRX shares fell $1.98 per share, or 21%, closing at $7.42 on March 24, 2026, after an FDA Warning Letter revealed that promotional communications about the Company's lead drug were false or misleading. The Court has set May 26, 2026 as the deadline to apply for lead plaintiff appointment.
The Named Individual Defendant
Dr. Patrick Soon-Shiong served as Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio at all relevant times. He is the sole individual defendant in this securities action. The lawsuit asserts that Soon-Shiong directly participated in the management of the Company at the highest levels, was privy to confidential proprietary information, and was directly involved in drafting, producing, reviewing, and disseminating the statements at issue.
Section 20(a) Control Person Framework
The complaint brings claims under Section 20(a) of the Securities Exchange Act of 1934, which imposes liability on individuals who controlled a company that violated Section 10(b). The action contends that Soon-Shiong, by virtue of his senior position, controlled the...
NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP alerts investors in ImmunityBio, Inc. (NASDAQ: IBRX) of a pending securities class action naming a senior executive as an ind...